This randomised study will compare pulsed field ablation and cryoballoon ablation with respect to ablation lesion quality as assessed by late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) at 3 months post-ablation. Patients scheduled for first-time AF ablation will be randomised in a 2:1 fashion to receive PVI-only, either by pulsed field ablation (Farapulse Pulsed Field Ablation System, Boston Scientific) or cryoballoon ablation (Medtronic Cryoballoon Ablation System).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients scheduled for first-time atrial fibrillation catheter ablation
Exclusion Criteria:
* age \<18 years
* long-standing persistent atrial fibrillation
* prior left atrial ablation
* pregnancy or lactation
* reduced left ventricular ejection fraction
* GFR \<30%
* BMI \>35%
* left atrial diameter \>55 mm
* cardiac implantable electronic device
Primary outcome measure(s)
LGE-CMR-determined ablation lesion quality — 3 months post-ablation Complete late gadolinium enhancement encircling both pulmonarz vein pairs, with discontinuations adding up to less than 10% of the total length of the circumference
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.